Please assess the completion status of the following clinical trial:

Trial Title: Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients in the age of 18 to 70 years~* Having a recent positive direct test for Sars-CoV-2~* Having mild or moderate COVID-19 symptoms with no indication for hospitalization due to SARS-CoV-2 infection (WHO Ordinal Scale 1-2)~Exclusion Criteria:~* Severe respiratory symptoms related to COVID-19 requiring oxygen or intensive care (high flow oxygen or mechanical ventilation or ECMO)~* Patients with preexisting pulmonary diseases requiring oxygen supply~* Patients with history of hypersensitivity to Camostat or Niclosamide or to any ingredients to any of the two drugs~* Patients with heart failure (NYHA III or NYHA IV)~* Patients with proven malignant tumor~* Patients diagnosed with influenza infection~* Pregnancy or breastfeeding~* Immunocompromised patients~* Creatinine clearance \< 60 mL/min~* aspartate aminotransferase (AST) / alanine aminotransferase (ALT) \> 2 times upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Niclosamide + Camostat (Type: ACTIVE_COMPARATOR): Patients will receive the combination of niclosamide chewing tablets (2000 mg, once daily) and camostat tablets (600 mg, 4-times daily) over a period of 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo orally over a period of 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).